JP2017504324A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504324A5 JP2017504324A5 JP2016544613A JP2016544613A JP2017504324A5 JP 2017504324 A5 JP2017504324 A5 JP 2017504324A5 JP 2016544613 A JP2016544613 A JP 2016544613A JP 2016544613 A JP2016544613 A JP 2016544613A JP 2017504324 A5 JP2017504324 A5 JP 2017504324A5
- Authority
- JP
- Japan
- Prior art keywords
- neoepitope
- subject
- cancer
- antigen
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 67
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 201000011510 cancer Diseases 0.000 claims description 28
- 239000000427 antigen Substances 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 206010069754 Acquired gene mutation Diseases 0.000 claims description 18
- 230000037439 somatic mutation Effects 0.000 claims description 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 11
- 238000002619 cancer immunotherapy Methods 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 108091035707 Consensus sequence Proteins 0.000 claims description 4
- 102000043129 MHC class I family Human genes 0.000 claims description 4
- 108091054437 MHC class I family Proteins 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 238000007482 whole exome sequencing Methods 0.000 claims description 3
- 239000012678 infectious agent Substances 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 claims description 2
- 108091008874 T cell receptors Proteins 0.000 claims 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 3
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 3
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 3
- 230000001580 bacterial effect Effects 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 238000012070 whole genome sequencing analysis Methods 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
- 229940123309 Immune checkpoint modulator Drugs 0.000 description 16
- 230000004044 response Effects 0.000 description 8
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 7
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 6
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 description 6
- 102100038078 CD276 antigen Human genes 0.000 description 6
- 101710185679 CD276 antigen Proteins 0.000 description 6
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 6
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 6
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 6
- 108010043610 KIR Receptors Proteins 0.000 description 6
- 102000002698 KIR Receptors Human genes 0.000 description 6
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 6
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 6
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 3
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 3
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 3
- 102100027207 CD27 antigen Human genes 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 3
- 102100028749 Neuritin Human genes 0.000 description 3
- 101710189685 Neuritin Proteins 0.000 description 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461923183P | 2014-01-02 | 2014-01-02 | |
| US61/923,183 | 2014-01-02 | ||
| US201462066034P | 2014-10-20 | 2014-10-20 | |
| US62/066,034 | 2014-10-20 | ||
| US201462072893P | 2014-10-30 | 2014-10-30 | |
| US62/072,893 | 2014-10-30 | ||
| PCT/US2014/072125 WO2015103037A2 (en) | 2014-01-02 | 2014-12-23 | Determinants of cancer response to immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017504324A JP2017504324A (ja) | 2017-02-09 |
| JP2017504324A5 true JP2017504324A5 (OSRAM) | 2018-02-08 |
Family
ID=53494217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016544613A Pending JP2017504324A (ja) | 2014-01-02 | 2014-12-23 | 免疫療法に対する癌応答の決定因子 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20160326597A1 (OSRAM) |
| EP (1) | EP3090066A4 (OSRAM) |
| JP (1) | JP2017504324A (OSRAM) |
| KR (1) | KR20160102314A (OSRAM) |
| CN (1) | CN106164289A (OSRAM) |
| AU (1) | AU2014374020A1 (OSRAM) |
| BR (1) | BR112016015399A2 (OSRAM) |
| CA (1) | CA2935214A1 (OSRAM) |
| CL (1) | CL2016001708A1 (OSRAM) |
| MX (1) | MX2016008771A (OSRAM) |
| PE (1) | PE20161344A1 (OSRAM) |
| PH (1) | PH12016501329A1 (OSRAM) |
| RU (1) | RU2707530C2 (OSRAM) |
| SG (2) | SG10201805674YA (OSRAM) |
| WO (1) | WO2015103037A2 (OSRAM) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732131B2 (en) | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
| KR20170080697A (ko) | 2014-11-13 | 2017-07-10 | 더 존스 홉킨스 유니버시티 | 관문 차단 및 미소부수체 불안정성 |
| MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| WO2016146143A1 (en) * | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| US20190099475A1 (en) | 2015-04-08 | 2019-04-04 | Nantomics, Llc | Cancer neoepitopes |
| WO2016172722A1 (en) * | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| EP3294324A1 (en) | 2015-05-13 | 2018-03-21 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
| GB201516047D0 (en) * | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| JP2018532736A (ja) * | 2015-10-12 | 2018-11-08 | ナントミクス，エルエルシー | チェックポイント阻害物質への感受性を予測するｍｓｉおよびネオエピトープの探索のための系、組成物、および方法 |
| EP3362929B1 (en) | 2015-10-12 | 2020-08-12 | Nantomics, LLC | Viral neoepitopes and uses thereof |
| KR20180083327A (ko) * | 2015-10-12 | 2018-07-20 | 난토믹스, 엘엘씨 | 바이러스성 암 네오에피토프를 위한 조성물 및 방법 |
| EP3719143B1 (en) * | 2015-10-23 | 2023-07-26 | Novartis AG | Method of deriving a value for percent biomarker positivity for selected cells present in a field of view |
| TWI733719B (zh) * | 2015-12-07 | 2021-07-21 | 美商河谷控股Ｉｐ有限責任公司 | 改善的組合物及用於新表位之病毒遞送的方法及其應用 |
| CA3008641A1 (en) | 2015-12-16 | 2017-06-22 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
| US20190015491A1 (en) * | 2016-01-08 | 2019-01-17 | Vaccibody As | Neoepitope rna cancer vaccine |
| CN108700566A (zh) | 2016-02-19 | 2018-10-23 | 河谷控股Ip有限责任公司 | 免疫原性调节的方法 |
| CN109476731A (zh) * | 2016-02-29 | 2019-03-15 | 基础医药有限公司 | 治疗癌症的方法 |
| KR102500659B1 (ko) | 2016-02-29 | 2023-02-16 | 제넨테크, 인크. | 암에 대한 치료 및 진단 방법 |
| CN109072227A (zh) * | 2016-03-15 | 2018-12-21 | 组库创世纪株式会社 | 用于免疫治疗的监测和诊断及治疗剂的设计 |
| RS65430B1 (sr) * | 2016-03-16 | 2024-05-31 | Amal Therapeutics Sa | Kombinacija modulatora imunološke kontrolne tačke i kompleksa koji sadrži peptid koji prodire u ćeliju, teret i tlr peptidni agonist za primenu u medicini |
| EP3468600A4 (en) * | 2016-06-10 | 2019-11-13 | IO Therapeutics, Inc. | RECEPTOR-ELECTIVE RETINOID AND REXINOID COMPOUNDS AND IMMUNOMODULATORS FOR CANCER IMMUNOTHERAPY |
| US20190247435A1 (en) * | 2016-06-29 | 2019-08-15 | The Johns Hopkins University | Neoantigens as targets for immunotherapy |
| KR102879364B1 (ko) | 2016-09-21 | 2025-11-04 | 아말 테라퓨틱스 에스에이 | 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체 |
| EP3516081A4 (en) * | 2016-09-23 | 2020-07-29 | Memorial Sloan Kettering Cancer Center | DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY |
| JP7579056B2 (ja) * | 2016-10-06 | 2024-11-07 | ジェネンテック， インコーポレイテッド | がんのための治療方法及び診断方法 |
| EP3548897A4 (en) | 2016-12-01 | 2020-08-12 | Nantomics, LLC | PRESENTATION AND TREATMENT OF TUMOR ANTIGENICITY |
| WO2018112449A2 (en) | 2016-12-16 | 2018-06-21 | Nant Holdings Ip, Llc | Live cell imaging systems and methods to validate triggering of immune response |
| WO2018132753A1 (en) * | 2017-01-13 | 2018-07-19 | Nantbio, Inc. | Validation of neoepitope-based treatment |
| US12331359B2 (en) | 2017-01-18 | 2025-06-17 | Michael Laessig | Neoantigens and uses thereof for treating cancer |
| WO2018146128A1 (en) * | 2017-02-07 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy |
| KR20190129094A (ko) * | 2017-03-17 | 2019-11-19 | 난토믹스, 엘엘씨 | cfRNA에 대한 액체 생검(LIQUID BIOPSY FOR cfRNA) |
| CA3058175A1 (en) * | 2017-03-31 | 2018-10-04 | Bristol-Myers Squibb Company | Methods of treating tumor |
| EP3631471A4 (en) | 2017-05-30 | 2021-06-30 | Nant Holdings IP, LLC | ENRICHMENT OF CIRCULATING TUMOR CELLS USING NEO-EPITOPIA |
| WO2018223092A1 (en) | 2017-06-02 | 2018-12-06 | Arizona Board Of Regents On Behalf Of Arizona State University | A method to create personalized cancer vaccines |
| EP4012713B1 (en) * | 2017-06-13 | 2025-10-29 | BostonGene Corporation | Systems and methods for generating, visualizing and classifying molecular functional profiles |
| GB201710815D0 (en) * | 2017-07-05 | 2017-08-16 | Francis Crick Inst Ltd | Method |
| WO2019055618A1 (en) | 2017-09-15 | 2019-03-21 | Arizona Board Of Regents On Behalf Of Arizona State University | METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY |
| RU2020113600A (ru) | 2017-09-20 | 2021-10-20 | Ридженерон Фармасьютикалз, Инк. | Способы иммунотерапии пациентов, опухоли которых характеризуются высокой нагрузкой пассажирскими генными мутациями |
| CN117987553A (zh) * | 2017-09-25 | 2024-05-07 | 纪念斯隆凯特琳癌症中心 | 肿瘤突变负荷和检查点免疫疗法 |
| US12474340B2 (en) | 2017-09-25 | 2025-11-18 | Nant Holdings Ip, Llc | Validation of neoepitope presentation |
| WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
| JP2020536894A (ja) | 2017-10-15 | 2020-12-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 腫瘍処置法 |
| EP3704268B1 (en) | 2017-11-03 | 2025-01-22 | Guardant Health, Inc. | Normalizing tumor mutation burden |
| US12163959B2 (en) * | 2017-11-09 | 2024-12-10 | The Trustees Of The University Of Pennsylvania | Extracellular vesicle proteins and their use for cancer diagnosis, predicting response to therapy, and treatment |
| EP3714275A4 (en) | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS |
| JP7299169B2 (ja) * | 2017-12-01 | 2023-06-27 | イルミナ インコーポレイテッド | 体細胞突然変異のクローン性を決定するための方法及びシステム |
| CN108009400B (zh) * | 2018-01-11 | 2018-07-06 | 至本医疗科技（上海）有限公司 | 全基因组肿瘤突变负荷预测方法、设备以及存储介质 |
| US11414698B2 (en) * | 2018-03-22 | 2022-08-16 | Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi | Method of quantifying mutant allele burden of target gene |
| WO2019210055A2 (en) | 2018-04-26 | 2019-10-31 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
| CA3107983A1 (en) | 2018-07-23 | 2020-01-30 | Guardant Health, Inc. | Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage |
| SG11202101400UA (en) | 2018-08-31 | 2021-03-30 | Guardant Health Inc | Microsatellite instability detection in cell-free dna |
| CN109371005B (zh) * | 2018-11-12 | 2022-09-30 | 上海市东方医院（同济大学附属东方医院） | 一种hla-0201限制性padi4表位多肽及其应用 |
| CN113194995A (zh) * | 2018-12-12 | 2021-07-30 | 免疫医疗有限责任公司 | 基于血液的肿瘤突变负荷预测非小细胞肺癌的总存活 |
| EP3899019A4 (en) * | 2018-12-21 | 2022-10-05 | Agency for Science, Technology and Research | METHOD OF PREDICTING THE BENEFITS OF IMMUNE CHECKPOINT INHIBITION THERAPY |
| AU2020256218A1 (en) * | 2019-04-05 | 2021-01-21 | Illumina, Inc. | Quantitative score of HLA diversity |
| WO2020242837A1 (en) * | 2019-05-24 | 2020-12-03 | Iuve, Inc. | A precision medicine method for cancer immunotherapy |
| WO2021067550A1 (en) | 2019-10-02 | 2021-04-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
| NL2024107B1 (en) * | 2019-10-26 | 2021-07-19 | Vitroscan B V | Compositions for Patient Specific Immunotherapy |
| CN111088349B (zh) * | 2020-02-14 | 2023-04-28 | 深圳市宝安区妇幼保健院 | Kir3dl1基因分型引物组及其应用 |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4000596A1 (en) * | 2020-11-17 | 2022-05-25 | The Boots Company plc | Tetrapeptide and compositions comprising tetrapeptides |
| EP4000595A1 (en) * | 2020-11-17 | 2022-05-25 | The Boots Company plc | Tetrapeptide and compositions comprising tetrapeptides |
| US20240192195A1 (en) * | 2021-04-10 | 2024-06-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | A multiomic approach to modeling of gene regulatory networks in multiple myeloma |
| JP2024534120A (ja) | 2021-08-24 | 2024-09-18 | ビオンテック・ソシエタス・エウロパエア | インビトロ転写技術 |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| WO2024216165A1 (en) | 2023-04-12 | 2024-10-17 | Icahn School Of Medicine At Mount Sinai | Computational methods for selecting personalized neoantigen vaccines |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9826143D0 (en) * | 1998-11-27 | 1999-01-20 | Ludwig Inst Cancer Res | Tumour rejection antigens |
| US9222938B2 (en) * | 2001-12-04 | 2015-12-29 | Michael Tainsky | Neoepitope detection of disease using protein arrays |
| EP2366717A3 (en) * | 2004-10-29 | 2011-12-14 | University of Southern California | Combination Cancer Immunotherapy with Co-Stimulatory Molecules |
| US20100099090A1 (en) * | 2007-03-05 | 2010-04-22 | Bristol-Mayers Squibb Company | Biomarkers and methods for determining sensitivity to ctla-4 antagonists |
| PT3023788T (pt) * | 2010-05-14 | 2020-05-18 | Massachusetts Gen Hospital | Composições de neoantigénios específicos de tumor para utilização no tratamento de tumores |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| WO2012159643A1 (en) * | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
-
2014
- 2014-12-23 SG SG10201805674YA patent/SG10201805674YA/en unknown
- 2014-12-23 US US15/109,464 patent/US20160326597A1/en not_active Abandoned
- 2014-12-23 MX MX2016008771A patent/MX2016008771A/es unknown
- 2014-12-23 SG SG11201605432RA patent/SG11201605432RA/en unknown
- 2014-12-23 CA CA2935214A patent/CA2935214A1/en not_active Abandoned
- 2014-12-23 RU RU2016131207A patent/RU2707530C2/ru not_active IP Right Cessation
- 2014-12-23 CN CN201480075287.2A patent/CN106164289A/zh active Pending
- 2014-12-23 WO PCT/US2014/072125 patent/WO2015103037A2/en not_active Ceased
- 2014-12-23 JP JP2016544613A patent/JP2017504324A/ja active Pending
- 2014-12-23 KR KR1020167021093A patent/KR20160102314A/ko not_active Withdrawn
- 2014-12-23 PE PE2016000989A patent/PE20161344A1/es unknown
- 2014-12-23 AU AU2014374020A patent/AU2014374020A1/en not_active Abandoned
- 2014-12-23 BR BR112016015399A patent/BR112016015399A2/pt not_active IP Right Cessation
- 2014-12-23 EP EP14876694.2A patent/EP3090066A4/en not_active Withdrawn
-
2016
- 2016-07-01 CL CL2016001708A patent/CL2016001708A1/es unknown
- 2016-07-04 PH PH12016501329A patent/PH12016501329A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017504324A5 (OSRAM) | ||
| Chiou et al. | Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery | |
| RU2016131207A (ru) | Детерминанты ответа раковой опухоли на иммунотерапию | |
| Khodadoust et al. | Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens | |
| Yang et al. | Advancing CAR T cell therapy through the use of multidimensional omics data | |
| Fehlings et al. | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment | |
| Bear et al. | Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting | |
| JP7430136B2 (ja) | 疲弊したｔ細胞に関連する疾患を治療するための方法および組成物 | |
| JP2018502828A5 (OSRAM) | ||
| CN113474840B (zh) | 用于预测hla ii类特异性表位及表征cd4+ t细胞的方法和系统 | |
| Topalian et al. | Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy | |
| WO2016081947A4 (en) | Determinants of cancer response to immunotherapy by pd-1 blockade | |
| Bauer et al. | The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma | |
| JP7073254B2 (ja) | 癌における「免疫チェックポイント介入」 | |
| JP2023159353A (ja) | Ｔ細胞疲弊を予防および逆転するためのエピジェネティック標的および転写標的の同定 | |
| Chen et al. | Characterization of a soluble B7-H3 (sB7-H3) spliced from the intron and analysis of sB7-H3 in the sera of patients with hepatocellular carcinoma | |
| Kiyotani et al. | Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens | |
| Hammerl et al. | Adoptive T cell therapy: new avenues leading to safe targets and powerful allies | |
| Verma et al. | Immunotherapy in extensive small cell lung cancer | |
| JP2014530009A5 (OSRAM) | ||
| JP2018524973A5 (OSRAM) | ||
| US11821027B2 (en) | Epigenetic analysis of cell therapy and related methods | |
| Choudhury et al. | Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies | |
| Zappasodi et al. | Strategies for predicting response to checkpoint inhibitors | |
| Cari et al. | Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis |